USA: Researchers have found in a new study that among adolescent and adult women with uncomplicated urinary tract infection, gepotidacin provides early symptom relief and test-of-cure symptom resolution rates comparable to nitrofurantoin. The findings of the study have been published in Clinical Infectious Diseases.Uncomplicated urinary tract infections (uUTIs) are among the most common bacterial infections affecting women and can cause distressing symptoms such as painful urination, urgency, and frequent urination that interfere with routine daily activities. Although treatment trials typically focus on bacterial clearance, the speed at which symptoms improve is a key concern for patients. The present analysis aimed to evaluate early symptom improvement during treatment for uUTI.The study was conducted by Amanda J Sheets and colleagues from GSK. Researchers performed a pooled analysis of data from two phase 3 randomized clinical trials, EAGLE-2 and EAGLE-3. These trials previously demonstrated that the investigational antibacterial agent Gepotidacin was noninferior to the commonly prescribed antibiotic Nitrofurantoin.The trials enrolled female participants aged 12 years and older who had at least two symptoms of uUTI along with laboratory evidence such as urinary nitrite positivity or pyuria, without complicating factors. In total, 3,136 participants were randomized to receive either oral gepotidacin 1500 mg twice daily or nitrofurantoin 100 mg twice daily for five days.Symptom severity was assessed at baseline (Day 1), during therapy (Days 2–4), and at the test-of-cure visit (Days 10–13). Researchers evaluated urinary symptoms using a standardized scoring system ranging from none to severe, generating a total symptom score between 0 and 12. The following were the key findings:At baseline, symptom severity was similar between the two groups, with mean symptom scores of 7.1 in the gepotidacin group and 7.2 in the nitrofurantoin group.During treatment, symptom scores decreased markedly, reaching a mean score of 3.6 in both groups at the on-therapy assessment.More than 80% of participants in both treatment arms experienced clinical improvement or complete resolution of symptoms during therapy.Among participants who initially reported moderate to severe symptoms affecting daily activities, about 53% in both groups reported improvement to mild or absent symptoms during treatment.By the test-of-cure visit, symptom improvement was observed in over 93% of participants receiving either gepotidacin or nitrofurantoin.The analysis defined improvement as any reduction in symptom score, which may not always represent a meaningful improvement in quality of life.To address this limitation, researchers also evaluated functional symptom improvement, focusing on patients’ ability to resume normal daily activities.Overall, the findings suggest that gepotidacin and nitrofurantoin provide similar and meaningful early relief of uUTI symptoms. The authors noted that gepotidacin may offer an alternative treatment option for patients who require therapy other than standard-of-care antibiotics and could help individuals resume normal daily activities soon after starting treatment. They also emphasized that early symptom response should be prioritized as an important outcome in future uUTI clinical trials.